Vaccination of macaques with SIV immunogens delivered by Venezuelan equine encephalitis virus replicon particle vectors followed by a mucosal challenge with SIVsmE660

Vaccine

Volumn 23, Issue 42, 2005, Pages 4969-4979

  Johnston, Robert E ^a,b   Johnson, Philip R ^c   Connell, Mary J ^c   Montefiori, David C ^d   West, Ande ^a   Collier, Martha L ^a   Cecil, Chad ^a,b,e   Swanstrom, Ronald ^a,b   Frelinger, Jeffrey A ^a   Davis, Nancy L ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e AlphaVax Inc   (United States)

Author keywords

Replicon; SIV; Vaccine

Indexed keywords

GAG PROTEIN; NEUTRALIZING ANTIBODY; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; INOCULATION; LYMPHOCYTE COUNT; MACACA; MOLECULAR CLONING; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REPLICON; RETROVIRUS INFECTION; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; VACCINATION; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS LOAD; VIRUS PARTICLE; VIRUS STRAIN; VIRUS VIRULENCE;

ANIMALS; ANTIBODIES, VIRAL; CD4 LYMPHOCYTE COUNT; DISEASE MODELS, ANIMAL; ENCEPHALITIS VIRUS, VENEZUELAN EQUINE; GENETIC VECTORS; IMMUNITY, CELLULAR; INJECTIONS, SUBCUTANEOUS; MACACA MULATTA; NEUTRALIZATION TESTS; REPLICON; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SYNTHETIC; VIRAL LOAD; VIRAL VACCINES;

EID: 24644447713     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.05.034     Document Type: Article

References (63)

1. P. Polacino, V. Stallard, D.C. Montefiori, C.R. Brown, B.A. Richardson, and W.R. Morton Protection of macaques against intrarectal infection by a combination immunization regimen with recombinant simian immunodeficiency virus SIVmne gp160 vaccines J Virol 73 1999 3134 3146
2. C.G. Murphy, W.T. Lucas, R.E. Means, S. Czajak, C.L. Hale, and J.D. Lifson Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus J Virol 74 2000 7745 7754
3. S. Crotty, C.J. Miller, B.L. Lohman, M.R. Neagu, L. Compton, and D. Lu Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors J Virol 75 2001 7435 7452
4. N.F. Rose, P.A. Marx, A. Luckay, D.F. Nixon, W.J. Moretto, and S.M. Donahoe An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants Cell 106 2001 539 554
5. R.R. Amara, F. Villinger, J.D. Altman, S.L. Lydy, S.P. O'Neil, and S.I. Staprans Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine Science 292 2001 69 74
6. P.L. Earl, L.S. Wyatt, D.C. Montefiori, M. Bilska, R. Woodward, and P.D. Markham Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric env protein boost in the SHIV rhesus macaque model Virology 294 2002 270 281
7. J.W. Shiver, T.M. Fu, L. Chen, D.R. Casimiro, M.E. Davies, and R.K. Evans Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity Nature 415 2002 331 335
8. +-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge J Virol 77 2003 11563 11577
9. P.N. Fultz, J. Stallworth, D. Porter, M. Novak, M.J. Anderson, and C.D. Morrow Immunogenicity in pig-tailed macaques of poliovirus replicons expressing HIV-1 and SIV antigens and protection against SHIV-89.6P disease Virology 315 2003 425 437
10. Johnson PR. Adeno-associated virus vectors. Abstracts of AIDS vaccine 2003, New York. NY; 2003. p. 69.
11. J. Zhao, J. Pinczewski, V.R. Gomez-Roman, D. Venzon, V.S. Kalyanaraman, and P.D. Markham Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIVmac251 challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen J Virol 77 2003 8354 8365
12. N.L. Letvin, Y. Huang, B.K. Chakrabarti, L. Xu, M.S. Seaman, and K. Beaudry Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys J Virol 78 2004 7490 7497
13. E. Ramsburg, N.F. Rose, P.A. Marx, M. Mefford, D.F. Nixon, and W.J. Moretto Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol J Virol 78 2004 3930 3940
14. D.H. Barouch, T-M. Fu, D.C. Montefiori, M.G. Lewis, J.W. Shiver, and N.L. Letvin Vaccine-elicited immune responses prevent clinical AIDS in SHIV89.6P-infected rhesus monkeys Immunol Lett 79 2001 57 61
15. Y. Tang, F. Villinger, S.I. Staprans, R.R. Amara, J.M. Smith, and J.G. Herndon Slowly declining levels of viral RNA and DNA in DNA/recombinant modified vaccinia virus Ankara-vaccinated macaques with controlled simian-human immunodeficiency virus SHIV-89.6P challenges J Virol 76 2002 10147 10154
16. T. Matano, M. Kobayashi, H. Igarashi, A. Takeda, H. Nakamura, and M. Kano Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial J Exp Med 199 2004 1709 1718
17. S. Santra, D.H. Barouch, B. Korioth-Schmitz, C.I. Lord, G.R. Krivulka, and F. Yu Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses Proc Natl Acad Sci USA 101 2004 11088 11093
18. R.A. Koup, J.T. Safrit, Y. Cao, C.A. Andrews, G. McLeod, and W. Borkowsky Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome J Virol 68 1994 4650 4655
19. P. Borrow, H. Lewicki, B.H. Hahn, G.M. Shaw, and M.B. Oldstone Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection J Virol 68 1994 6103 6110
20. T. Matano, R. Shibata, C. Siemon, M. Connors, H. Lane, and M.A. Martin Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques J Virol 72 1998 164 169
21. X. Jin, D.E. Bauer, S.E. Tuttleton, S. Lewin, A. Gettie, and J. Blanchard Dramatic rise in plasma viremia after CD8+ T cell depletion in simian immunodeficiency virus-infected macaques J Exp Med 189 1999 991 998
22. J.E. Schmitz, M.J. Kuroda, S. Santra, V.G. Sasseville, M.A. Simon, and M.A. Lifton Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes Science 283 1999 857 860
23. + T cell depletion on virus replication in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine J Exp Med 191 2000 1921 1931
24. J.R. Mascola, M.G. Lewis, G. Stiegler, D. Harris, T.C. VanCott, and D. Hayes Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies J Virol 73 1999 4009 4018
25. R. Shibata, T. Igarashi, N. Haigwood, A. Buckler-White, R. Ogert, and W. Ross Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys Nat Med 5 1999 204 210
26. L. Zhang, R.M. Ribeiro, J.R. Mascola, M.G. Lewis, G. Stiegler, and H. Katinger Effects of antibody on viral kinetics in simian/human immunodeficiency virus infection: implications for vaccination J Virol 78 2004 5520 5522
27. N.L. Haigwood, A. Watson, W.F. Sutton, J. McClure, A. Lewis, and J. Ranchalis Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile Immunol Lett 51 1-2 1996 107 114 Jun
28. D.H. Barouch, J. Kunstman, M.J. Kuroda, J.E. Schmitz, S. Santra, and F.W. Peyerl Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes Nature 415 2002 335 339
29. Bertley FMN, P.A. Kozlowski, S-W. Wang, J. Chappelle, J. Patel, and O. Sonuyi Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates J Immunol 172 2004 3745 3757
30. S.P. Mossman, C.C. Pierce, A.J. Watson, M.N. Robertson, D.C. Montefiori, and L. Kuller Protective immunity toSIV challenge elicited by vaccination of macaques with multigenic DNA vaccines producing virus-like particles AIDS Res Hum Retrov 20 2004 425 434
31. Negri DRM, S. Baroncelli, S. Catone, A. Comini, Z. Michelini, and M.T. Maggiorella Protective efficacy of a multicomponent vector vaccine in cynomolgus monkeys after intrarectal simian immunodeficiency virus challenge J Gen Virol 85 2004 1191 1201
32. L.J. Patterson, N. Malkevitch, D. Venzon, J. Pinczewski, V.R. Gomez-Roman, and L. Wang Protection against mucosal simian immunodeficiency virus SIVmac251 challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting J Virol 78 2004 2212 2221
33. R.R. Amara, J.M. Smith, S.I. Staprans, D.C. Montefiori, F. Villinger, and J.D. Altman Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine J Virol 76 2002 6138 6146
34. J.R. Mascola, G. Stiegler, T.C. VanCott, H. Katinger, C.B. Carpenter, and C.E. Hanson Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies Nat Med 6 2000 207 210
35. P. Paren, P.A. Marx, A.J. Hessell, A. Luckay, J. Harouse, and C. Cheng-Mayer Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro J Virol 75 2001 8340 8347
36. K.A. Reimann, J.T. Li, R. Veazey, M. Halloran, I-W. Park, and G.B. Karlsson A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys J Virol 70 1996 6922 6928
37. M.B. Feinberg, and J.P. Moore AIDS vaccine models: challenging challenge viruses Nat Med 8 2002 207 210
38. V.M. Hirsch, and P.R. Johnson Pathogenic diversity of simian immunodeficiency viruses Virus Res 1994 32183 32203
39. N.L. Davis, I.J. Caley, K.W. Brown, M.R. Betts, D.M. Irlbeck, and K.M. McGrath Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles J Virol 74 2000 371 378
40. G.H. MacDonald, and R.E. Johnston Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis J Virol 74 2000 914 922
41. P.B. Jahrling, and E.H. Stephenson Protective efficacies of live attenuated and formaldehyde-inactivated Venezuelan equine encephalitis virus vaccines against aerosol challenge in hamsters J Clin Microbiol 19 1984 429 431
42. N.L. Davis, K.W. Brown, and R.E. Johnston A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge J Virol 70 1996 3781 3787
43. P.C. Charles, K.W. Brown, N.L. Davis, M.K. Hart, and R.E. Johnston Mucosal immunity induced by parenteral immunization with a live attenuated Venezuelan equine encephalitis virus vaccine candidate Virology 228 1997 153 160
44. P. Pushko, M. Parker, G.V. Ludwig, N.L. Davis, R.E. Johnston, and J.F. Smith Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo Virology 239 1997 389 401
45. P. Liljestrom, and H. Garoff A new generation of animal cell expression vectors based on the Semliki Forest virus replicon Biotechnology 9 1991 1356 1361
46. F.B. Grieder, N.L. Davis, J.F. Aronson, P.C. Charles, D.C. Sellon, and K. Suzuki Specific restrictions in the progression of Venezuelan equine encephalitis virus-induced disease resulting from single amino acid changes in the glycoproteins Virology 206 1995 994 1006
47. D. Montefiori, T.W. Baba, A. Li, M. Bilska, and R.M. Ruprecht Neutralizing and infection-enhancing antibody responses do not correlate with the differential pathogenicity of SIVmac239delata3 in adult and infant rhesus monkeys J Immunol 157 1996 5528 5535
48. M. Matsui, C.E. Hioe, and J.A. Frelinger Roles of the sis peptide-binding pockets of the HLA-A2 molecule in allorecognition by human cytotoxic T-cell clones Proc Natl Acad Sci. USA 90 1993 674 678
49. M.S. Urdea, J.C. Wilber, T. Yeghiazarian, J.A. Todd, D.G. Kern, and S-J. Fong Direct and quantitative detection of HIV-1 RNA in human plasma with a branched DNA signal amplification assay AIDS 7 Suppl. 2 1993 11 S14
50. M.J. Schell, and B. Singh The reduced monotonic regression method J Am Stat Assoc 92 1997 128 135
51. P. Pushko, M. Bray, G.V. Ludwig, M. Parker, A. Schmaljohn, and A. Sanchez Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus Vaccine 19 2000 142 153
52. P. Pushko, J. Geisbert, M. Parker, P. Jahrling, and J. Smith Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses J Virol 75 2001 11677 11685
53. S. Schultz-Cherry, J.K. Dybing, N.L. Davis, C. Williamson, D. Suarez, and R. Johnston Influenza virus (A/HK/156/97) hemagglutinin expressed by an alphavirus replicon system protects chickens against lethal infection with Hong Kong-origin H5N1 viruses Virology 278 2000 55 59
54. Balasuriya UBR, H.W. Heidner, J.F. Hedges, J.C. Williams, N.L. Davis, and R.E. Johnston Expression of the two major envelope proteins of equine arteritis virus as a heterodimer is necessary for induction of neutralizing antibodies in mice immunized with recombinant Venezuelan equine encephalitis virus replicon particles J Virol 74 2000 10623 10630
55. Balasuriya UBR, H.W. Heidner, N.L. Davis, H.M. Wagner, P.J. Hullinger, and J.F. Hedges Alphavirus replicon particles expressing the two major envelope proteins of equine arteritis virus induce high level protection against challenge with virulent virus in vaccinated horses Vaccine 20 2002 1609 1617
56. M. Hevey, D. Negley, P. Pushko, J. Smith, and A. Schmaljohn Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates Virology 251 1998 28 37
57. Wilson F J.A., M. Bray, R. Bakken, and M.K. Hart Vaccine potential of Ebola virus VP24, VP30, VP35 and VP40 proteins Virology 286 2001 384 390
58. Lee F J.S., B.K. Dyas, S.S. Nystrom, C.M. Lind, J.F. Smith, and R.G. Ulrich Immune protection against staphylococcal enterotoxin-induced toxic shock by vaccination with a Venezuelan equine encephalitis virus replicon J Infect Dis 185 2002 1192 1196
59. Lee F J.S., A.G. Hadjipanayis, and S.L. Welkos Venezuelan equine encephalitis virus-vectored vaccines protect mice against anthrax spore challenge Infect Immun 71 2003 1491 1496
60. J.S. Lee, P. Pushko, M.D. Parker, M.T. Dertzbaugh, L.A. Smith, and J.F. Smith Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system Infect Immun 69 2001 5709 5715
61. B.J. Rybarczyk, D. Montefiori, P.R. Johnson, A. West, R.E. Johnston, and R. Swanstrom Correlation between env V1/V2 region diversification and neutralizing antibodies during primary infection by simian immunodeficiency virus sm in rhesus macaques Virology 78 2004 3561 3571
62. + T cells in control of SIV replication J Clin Invest 113 2004 836 845
63. S.I. Staprans, A.P. Barry, G. Silvestri, J.T. Safrit, N. Kozyr, and B. Sumpter Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein Proc Natl Acad Sci USA 101 2004 13026 13031